Skip to main content

Table 5 Treatment-emergent adverse events (TEAEs), overview of all patients (N = 761)

From: Comparably high retention and low relapse rates in different subpopulations of bipolar patients in a German non-interventional study

Patients with: Total sample N = 761 OM N = 186 LM N = 152 AM N = 216  OLC N = 47 OAC N = 68 OC N = 48 OMS N = 44
N % N % N % N % N % N % N % N %
Any TEAE 113 14.9 21 11.3 27 17.8 31 14.4 9 19.2 8 11.8 7 14.6 10 22.7
 Related TEAE 78 10.3 14 7.5 19 12.5 23 10.7 6 12.8 6 8.8 3 6.3 7 15.9
Any SAE 8 1.1 0 0.0 3 2.0 1 0.5 1 2.1 0 0.0 2 4.2 1 2.3
 Related SAE 1 0.1 0 0.0 1 0.7 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
TEAE leading to discontinuation 7 0.9 0 0.0 2 1.3 1 0.5 1 2.1 0 0.0 2 4.2 1 2.3
Lethal outcome 4 0.5 0 0.0 0 0.0 1 0.5 1 2.1 0 0.0 2 4.2 0 0.0
  1. Abbreviations: N number of patients, OM Olanzapine monotherapy, LM Lithium monotherapy, AM Anticonvulsive monotherapy, OLC Olanzapine/lithium combination therapy, OAC Olanzapine/anticonvulsive combination therapy, OC Other combinations of mood-stabilizers, OMS Other mood stabilizing therapy, TEAE treatment emergent adverse events, SAE serious adverse events.